The U.S. Department of Health and Human Services (HHS) recently recommended reclassifying cannabis from a Schedule I to a Schedule III controlled substance. This decision was based on a scientific review of the potential medical benefits and risks. The Drug Enforcement Administration (DEA) will now review the HHS recommendation and public comments during upcoming hearings (January 21 to March 3, 2025). The DEA will then make a final decision on whether to reschedule cannabis.

Ahead of the upcoming DEA hearings, Dr. Igor Grant, MD, sat down to discuss the potential impact of cannabis rescheduling on research.